<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061358</url>
  </required_header>
  <id_info>
    <org_study_id>DMID 13-0001</org_study_id>
    <secondary_id>KQA71264</secondary_id>
    <secondary_id>UV-DEN-0001</secondary_id>
    <nct_id>NCT02061358</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects</brief_title>
  <acronym>UV</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unither Virology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Unither Virology</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the safety and tolerability of a single-ascending oral dose of
      UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption
      and elimination following a single dose of UV-4B in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The causative agent of dengue fever is Dengue Virus (DENV), a member of the flavivirus
      genus. There are four DENV serotypes.  Infection with one serotype results in lifelong
      immunity against that serotype, but only limited short-term cross-protection from infection
      with the other serotypes.  Immunity to one serotype has a downside as subsequent infections
      by other serotypes increase the risk of developing more severe forms of dengue, which
      includes the most lethal form of the disease, dengue hemorrhagic fever.  Traditional
      epidemiologic and serologic-based estimates suggest a range of 50 to 100 million DENV
      infections per year distributed over 100 countries.  Recent cartographic-based modeling
      studies suggest that up to 390 million of dengue infections per year, of which 96 million
      are associated with clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation and occurrence of AEs and serious AEs (SAEs)</measure>
    <time_frame>Up to 5 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of changes from baseline for vital signs, ECGs, and clinical laboratory tests</measure>
    <time_frame>Up to 5 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of UV-4 plasma and urine concentrations and PK parameters</measure>
    <time_frame>Up to 5 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Dengue Fever</condition>
  <arm_group>
    <arm_group_label>Cohort 1, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1; UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1; UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1, UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1; UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1; UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1, UV-4B:Placebo, Group b: 5 active ingredients and 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1; UV-4B:Placebo, Group b: 5 active ingredients and one placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8, groups (a) and (b)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group a: 1:1, UV-4B:Placebo, Group b: 5 active ingredients and one placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UV-4B</intervention_name>
    <description>Dose range 3 mg to 1000 mg, oral solution, single dose</description>
    <arm_group_label>Cohort 1, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 2, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 3, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 4, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 5, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 6, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 7, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 8, groups (a) and (b)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose range 3 mg to 1000 mg, oral solution, single dose</description>
    <arm_group_label>Cohort 1, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 2, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 3, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 4, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 5, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 6, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 7, groups (a) and (b)</arm_group_label>
    <arm_group_label>Cohort 8, groups (a) and (b)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects

          -  Non-child bearing potential

        Exclusion Criteria:

          -  Health conditions

          -  Taking other prescription and non-prescription dugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne R. Baker, RN</last_name>
    <role>Study Director</role>
    <affiliation>Office of Biodefense, Research, Resources and Translational Division of Microbiology and Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Echalier, MS,MBA</last_name>
    <phone>913-708-6873</phone>
    <email>benjamin.echalier@quintiles.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marla Woodfolk, BS</last_name>
    <phone>202-350-4523</phone>
    <email>mwoodfolk@unithervirology.com</email>
  </overall_contact_backup>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Dengue Hemorrhagic Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
